Extended Data Fig. 5

Cost-effectiveness across 78-LMICs assuming (A) Lower bound assumptions for all costs (B) Upper bound assumptions for all costs (C) Lower bound assumptions for HPV test costs (all other costs at base case) (D) Upper bound assumptions for HPV test costs (all other costs at base case) (E) Upper bound assumptions for Cancer treatment costs (all other costs at base case). *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV16/18 positive women treated after assessment of eligibility for ablative treatment; women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA.0% discount rate for effect, 3% discount rate for cost HALY: health-adjusted life-years.